Carmustine

卡莫司汀

Report date: 2024/09/05 17:24:05
NME

Base Information

Drug NameCarmustine
Drug Alias Namecarmustina卡莫司厅卡氮芥Carmustinum亚硝脲氮芥 +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursNeoplasm Metastasis +[14] 
Global Approved IndicationsBrain NeoplasmsMultiple MyelomaMedulloblastoma +[8] 
Approved Indications in ChinaBrain NeoplasmsAstrocytoma
Original Approved Country/TerritoryUnited States
Original Approved Date1977/03/07
Country/TerritoryCanadaUnited StatesNetherlands +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEmcure Pharma
China Registration ClassN/A

Develop Information

Active CompaniesWeill Medical College of Cornell UniversityH Lee Moffitt Cancer Center & Research InstituteUniversity Of Washington +[7] 
Inactive CompaniesLisata Therapeutics IncDirect Therapeutics IncInsys Therapeutics Inc +[8] 
Active IndicationsBrain NeoplasmsMultiple MyelomaMedulloblastoma +[10] 
Inactive IndicationsCNS Embryonal TumorSolid tumoursNeoplasm Metastasis +[4] 

Other Information

ATC CodeL01AD01
Related LinksWikipediaDrugBankKEGG